About admin

This author has not yet filled in any details.
So far admin has created 50 blog entries.

Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.

On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. (“BVF”) comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), representing a purchase price per share of $0.87.

As part of the financing, in a second potential closing, BVF will have the right, following a successful end of phase 2 meeting with the U.S. Food and Drug Administration (“FDA”), among other closing conditions, to purchase units at a per unit purchase price of $1.50, which units will consist of common shares (or equivalents), as well as a common share warrant to purchase up to one and a half common shares at an exercise price of $2.03 per share. If this option is exercised in full, BVF will receive 20 million common shares plus common share warrants to purchase 20 million NLS common shares at $2.03 per share.

 Laidlaw & Company (UK) Ltd. acted as exclusive introducing broker for the offering.

Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.2022-12-19T05:43:59+00:00

Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.

Perfect Moment is a luxury sportswear brand that has become known as an iconic staple in winter wear. The Perfect Moment collections marry the extreme demands of nature with the world of fashion and can be found at Selfridges, Net-A-Porter, Matches, Saks Fifth Avenue, Neiman Marcus, Bloomingdales and FWRD.

Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.2022-07-20T20:37:11+00:00

Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering

Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo.

Read article: https://www.prnewswire.com/news-releases/cohen–steers-real-estate-opportunities-and-income-fund-rlty-raises-305-million-301490198.html

 

 

 

Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering2022-03-30T17:06:36+00:00

Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.

Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products.

Read Article: https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/cingulate-inc-announces-pricing-25-020500801.html

 

Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.2022-01-06T15:45:44+00:00
Go to Top